Dossier assessment
Inotuzumab ozogamicin (acute lymphocytic leukaemia) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Report documents
-
Dossier assessment
Inotuzumab ozogamicin (acute lymphocytic leukaemia) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V
Additional information
Federal Joint Committee (G-BA)
2018-01-18 A G-BA decision was published.
Project details
- Project no.
- G17-07
- Commission
- Commission awarded on 14.07.2017 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Health Economics
- Topic
- Cancer
- Note
-
In accordance with § 35a (para. 1, sentence 10) Social Code Book V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. For the Inotuzumab ozogamicin report commissioned by the Federal Joint Committee (G-BA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. The resolution on the extent of added benefit is passed by the G-BA after the hearing. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA Website.
Connected Projects
-
Dossier assessment
Inotuzumab ozogamicin (relapsed/refractory ALL, children >= 1 year ) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Status: Commission completed